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Abstract
Objective: Cognitive impairment is frequent in Parkinson’s disease, but the
underlying mechanisms are insufficiently understood. Because cortical metabo-
lism is reduced in Parkinson’s disease and closely associated with cognitive
impairment, and CSF amyloid-b species are reduced and correlate with neu-
ropsychological performance in Parkinson’s disease, and amyloid-b release to
interstitial fluid may be related to synaptic activity; we hypothesize that synapse
dysfunction links cortical hypometabolism, reduced CSF amyloid-b, and presy-
naptic deposits of a-synuclein. We expect a correlation between hypometabo-
lism, CSF amyloid-b, and the synapse related-markers CSF neurogranin and a-
synuclein. Methods: Thirty patients with mild-to-moderate Parkinson’s disease
and 26 healthy controls underwent a clinical assessment, lumbar puncture,
MRI, 18F-fludeoxyglucose-PET, and a neuropsychological test battery (repeated
for the patients after 2 years). Results: All subjects had CSF amyloid-b 1-42
within normal range. In Parkinson’s disease, we found strong significant corre-
lations between cortical glucose metabolism, CSF Ab, a-synuclein, and neuro-
granin. All PET CSF biomarker-based cortical clusters correlated strongly with
cognitive parameters. CSF neurogranin levels were significantly lower in mild-
to-moderate Parkinson’s disease compared to controls, correlated with amyloid-
b and a-synuclein, and with motor stage. There was little change in cognition
after 2 years, but the cognitive tests that were significantly different, were also
significantly associated with cortical metabolism. No such correlations were
found in the control group. Interpretation: CSF Ab, a-synuclein, and neuro-
granin concentrations are related to cortical metabolism and cognitive decline.
Synaptic dysfunction due to Ab and a-synuclein dysmetabolism may be central
in the evolution of cognitive impairment in Parkinson’s disease.
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Introduction
Cognitive impairment is an important nonmotor symp-
tom of Parkinson’s disease (PD).1 Mean duration from
clinical disease onset to dementia is 10 years, but cogni-
tive impairment has been demonstrated already at the
time of diagnosis.2
Several factors argue for early involvement of synaptic
pathology in PD. Many of the proteins relevant in PD
pathophysiology are involved in synaptic physiology (re-
viewed in3). a-synuclein is considered the core pathologi-
cal substrate of PD, and in addition to accumulation in
Lewy bodies, a major deposition site of CNS oligomeric
a-synuclein is the presynapse, accompanied by transsy-
naptic dendritic spine loss.4,5 The presynaptic terminal is
the main site of function for both amyloid precursor pro-
tein (APP) and a-synuclein. a-synuclein is linked to
synaptic-vesicle complex formation and APP to synaptic-
vesicle docking and priming. Neurogranin, a substrate of
protein kinase C, is abundantly expressed, and located
preferentially at the postsynaptic dendritic spine plasma
membrane.6
Intracellular metabolism of these proteins is performed
by overlapping sets of enzymes and subcellular compart-
ments.7–10 Presynaptic activity and endocytosis influence
release of amyloid-b (Ab) species to the interstitial fluid.11
APP is initially cleaved at the presynaptic terminal to sev-
eral biologically active metabolites, including Ab 1-38
(Ab38), Ab 1-40 (Ab40), and Ab 1-42 (Ab42), the latter
particularly prone to brain parenchymal deposition.12,13
Most studies of CSF Ab species in PD have reported
slight reductions.14,15 We and others have found a correla-
tion between CSF Ab42 levels and memory performance in
PD,15,16 also in subjects with normal CSF Ab42 levels (thus
without evidence for amyloid plaques).15,17 These changes
relate to hippocampus subfield volumes18; experimental
studies show detrimental preplaque Ab effects on synaptic
function,19 and human Ab turnover decreases from
approximately 40 years of age,20 suggesting preplaque
effects of Ab on cognition and synaptic physiology.
MRI studies show that slight gray matter atrophy is
involved in PD cognitive decline.21 Studies combining
neuroimaging and CSF in PD are scarce, but CSF Ab cor-
relate with reduced gray matter volume and associated
neuropsychological function.22,23 FDG-PET studies have
identified a widespread, specific pattern of reduced glu-
cose metabolism in PD,24 most prominent in the fron-
toparietal and occipital cortices, even in the early stages
of the disease.25 Cerebral glucose metabolism reflects cor-
tical activation and synaptic density.26 Several studies
associate this hypometabolism with cognitive impairment,
suggesting that hypometabolism in PD primarily reflects
cognitive deterioration.27,28 Though a very recent
postmortem study suggests that loss of synaptic markers
predicts cognitive decline in Lewy body diseases,29 to the
best of our knowledge, no direct links have been estab-
lished between reduced glucose metabolism in PD and
independent synaptic markers.
Because (1) cortical glucose metabolism is reduced and
correlates with cognitive impairment in PD, and (2) CSF
Ab species are decreased and correlate with neuropsycho-
logical performance, and amyloid-b release to interstitial
fluid may be related to synaptic activity; we hypothesize
that synapse dysfunction is a common link between corti-
cal hypometabolism, CSF amyloid-b concentrations, and
presynaptic deposits of a-synuclein. We thus expect to
find a correlation between levels of CSF Ab species and
relative glucose metabolism, and also to possible markers
of synaptic dysfunction or loss, such as CSF a-synuclein
and neurogranin.
Materials and Methods
Subjects
This study is based on an ongoing longitudinal follow-up
of patients in a university hospital-based neurological
clinic. Thirty nondemented patients with mild-to-moder-
ate stage PD were recruited between 2011 and 2014 and
examined by a neurologist with extensive experience in
movement disorders, as previously described.15
The patient group and inclusion criteria in this study is
the same (aside from one subject excluded due to missing
FDG-PET) as the one described in ref 15. In short, inclu-
sion criteria were diagnosis of PD according to the UK
Parkinson’s Disease Society Brain Bank clinical diagnostic
criteria,30 Hoehn and Yahr stage <3, and disease duration
<6 years. All PD subjects had a pathological dopamine
transporter single photon emission computed tomography
(DaT-SPECT). Exclusion criteria were dementia (see
below for procedure) and other somatic or psychiatric
diseases that might contribute to cognitive impairment.
The Unified Parkinson’s Disease Rating Scale (UPDRS),
part III motor examination and Hoehn & Yahr staging
were performed. Patients had their medication as usual
when assessed. Total daily levodopa equivalent dose was
calculated. All PD subjects underwent cognitive assess-
ment employing a well-validated neuropsychological test
battery thoroughly described previously.15,31 The battery
covers memory: Delayed verbal recall (Rey Auditory Ver-
bal Learning Test (RAVLT)),32 and Delayed visual repro-
duction (Rey Complex Figure Test (RCFT)), (Meyers &
Meyers, 1995) and aspects of executive functions: Psy-
chomotor speed (Trail Making Test-A (TMT-A)), Divided
attention (Trail Making Test-B (TMT-B)) (Reitan &
Wolfson 1985), Word fluency (Controlled Oral Word
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Association Test (COWAT)) (Benton & Hamsher 1989),
and Response inhibition (Stroop Color-Word, D-KEFS)
(Delis et al., 2001). All examinations were conducted
within a 3-month period, and repeated after 2 years for
the PD subjects.
In addition to PD patients, a healthy control group was
included. Healthy controls were recruited from spouses of
included patients (three subjects), and the remaining con-
trols were recruited before lumbar puncture in conjunc-
tion with orthopedic surgery. Twenty-six subjects
assented and successfully underwent MRI and FDG-PET.
Exclusion criteria were as for PD, in addition to relevant
subjective cognitive memory symptoms.
All subjects gave their written consent, and the Regio-
nal Committee for Medical and Health Research Ethics
South-East evaluated (based on the Norwegian Health
and Research Act and the Helsinki Declaration of 1964;
revised 2013) and approved the study. All further study
conduct was based on and in line with these guidelines.
CSF analysis
CSF samples were collected from all participants by lum-
bar puncture, performed between 9 and 12 AM, and con-
secutively after inclusion. Following lumbar puncture and
standardized handling, CSF Ab42 > 700 ng/L were con-
sidered normal.
CSF Ab38, Ab40, and total a-synuclein were analyzed
with electrochemiluminescence immunoassays (Meso
Scale Discovery, US) in all PD patients. Due to possible
effects of hemolysis, total a-synuclein were only included
if CSF hemoglobin was <350 ng/mL. a-synuclein values
for five patients were thus excluded.
CSF neurogranin concentration was measured using a
previously described in-house ELISA.6 Briefly, an assay
based on the monoclonal antibody Ng7 (epitope includ-
ing amino acids 52–65 on neurogranin) was used for cap-
ture, a polyclonal neurogranin anti-rabbit antibody
(ab23570; Upstate Biotechnology, Lake Placid, NY, USA)
for detection, and full-length neurogranin protein as cali-
brator. We were able to measure neurogranin concentra-
tions in all included PD patients. For 19 of the 26
included controls there was sufficient CSF available to
assess neurogranin concentrations, and we added an addi-
tional 11 controls for which there was no available PET
data. (The neurogranin healthy control material, N = 30,
mean age 61.5 [range: 40–78; SD: 9.34], 18 females.)
FDG-PET and MRI imaging
FDG-PET/CT imaging was performed with a Siemens
Biograph 64 PET/CT scanner for the PD group, and a
Siemens Biograph 16 PET/CT scanner for the healthy
control group. All subjects fasted at least 4 h before image
acquisition, and had an intravenous bolus of 218 MBq
(23 MBq) injected, 45 min prior to scanning. A low-
dose CT scan for attenuation correction was acquired.
Patients were scanned for 15 min in three-dimensional
mode using one bed position (axial range = 16 cm).
Acquired data were corrected for random events, dead
time, attenuation (CT-derived l-map), scatter (model
based), and decay. PET volumes were reconstructed using
an iterative algorithm (OSEM 2D, four iterations, eight
subsets), and a postreconstruction three-dimensional
Gaussian filter of width 3.5 mm full-width at half maxi-
mum was applied. The axial image format was 256 9 256
(pixel size: 2.67 mm 9 2.67 mm), with a slice thickness
of 2.00 mm. Blood glucose at FDG injection time was
measured routinely, and the patient was excluded if blood
glucose exceeded 8.0 mmol/L.
For both PD and control subjects, MRI scans were
acquired on a Philips Achieva 3 Tesla system. A single
three-dimensional turbo field echo (TFE) sequence was
acquired for morphometrics. Cortical reconstruction and
volumetric segmentation was performed with FreeSur-
fer.33,34 The exact sequence parameters and reconstruction
methods are described elsewhere.35
Whole head PET volumes were coregistered with the
anatomical volume using a rigid body spatial registration
as implemented in the Spatial Parametrical Mapping
(SPM 8, Wellcome Trust Centre for Neuroimaging, UCL,
UK) co-registration tool. PET volumes were resliced into
1 mm MRI. For each subject, a voxel-based intensity nor-
malization to the mean uptake in the cerebellar white
matter was performed. (Prior to intensity normalization,
the cerebellar white matter mask was eroded to avoid
influence due to partial volume effects, inaccurate seg-
mentation, or coregistration). Intensity normalized vol-
umes were used for all further analyses. Because there is
both global cerebral and cerebellar cortical hypometabo-
lism in PD, neither global cortical mean nor cerebellar
cortical normalization were suitable. We therefore chose
to normalize the FDG-PET uptakes against mean cerebel-
lar white matter.25
Statistical analysis
Statistical maps were generated using the general linear
model as implemented in FreeSurfer. Auxiliary statistical
analyses were performed using IBM SPSS version 22
(Chicago, IL). Statistical maps of correlations (while cor-
recting for effects of age and gender) between normalized
FDG-PET uptake (or cortical thickness) and each CSF
biomarker concentration were created. This operation was
performed separately in the PD and control groups. Also,
similar statistical maps of correlations between cortical
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thickness and CSF biomarker concentrations were created.
These statistical operations on global data and surface
maps were generated by computing a general linear
model of the effects of CSF biomarker concentrations on
FDG uptake (or cortical thickness) at each vertex, while
controlling for effects of age and gender. A cluster-wise
correction for multiple comparisons was employed, based
on ref 36. A cluster-forming threshold of P < 0.01 was
chosen, and only clusters with a cluster-wise P < 0.01
(Bonferroni corrected for examining both hemispheres)
were kept.
The coefficient of determination, R2 was determined
for the relation between CSF biomarkers (separately) and
FDG uptake or cortical thickness (in pertinent areas as
determined above). The effects of age and sex were
regressed out of mean FDG uptake or cortical thickness,
and the resulting residual was entered in a simple regres-
sion model as dependent variables, with the CSF biomar-
ker concentration as explanatory variable.
To assess the relationship with cognitive function,
mean FDG uptake (corrected for age and sex) in the per-
tinent areas as determined above for each CSF biomarker
was also correlated (Spearman) with T-scores of neu-
ropsychologic tests.
According to examination of histograms and as
assessed by the Kolmogorov–Smirnov test of normality,
CSF neurogranin concentrations were not normally dis-
tributed in neither the PD nor the control group. We
therefore assessed group differences using Mann–Whitney
U. There were no significant correlations (Spearman’s
rho) between CSF neurogranin concentrations and age or
sex (neither within the PD group nor within the control
group). We did therefore not correct for age or sex when
comparing the groups. One outlier in the PD group with
values 10–20 times the mean in the group, was removed,
but included in additional analyses for reference.
Within the PD group, the distribution of CSF neuro-
granin, Ab38, 40, and 42 concentrations as well as
UPDRS scores were borderline normally distributed
according to examination of histograms and as assessed
by the Kolmogorov–Smirnov test of normality. We there-
fore chose to assess the correlation between these vari-
ables with Spearman correlations. (The estimations of
these correlations were repeated with parametric Pearson
correlations with very similar results, data not shown.)
Two-year follow-up cognitive data were available for
the PD subjects. To assess the association between cogni-
tion, time, and FDG-PET clusters as determined above, a
mixed models approach was used: each of the examined
neuropsychological variables were entered as dependent
variables accounting for repeated measures (in separate
models) with age, the FDG-PET cluster corresponding to
CSF Ab42, and also an interaction between time and the
FDG-PET cluster (to model the association between
FDG-PET and change over time) as independent vari-
ables. A priori, the FDG-PET cluster corresponding to
CSF Ab42 was chosen for this analysis because it is one
of the larger, representative clusters and the well-docu-
mented role of Ab42 in synaptic pathology.
Results
Demographical, CSF, and
neuropsychological characteristics of the
groups
There were no significant differences in age, gender com-
position, education, or MMSE between the PD and the
healthy control group. Neuropsychological function was in
the normal range for both groups, except slightly below
normal on a measure of divided attention in the PD group.
Group composition and demographics are outlined in
Table 1 and neuropsychological characteristics in Table 2.
Relationship between the CSF biomarkers
CSF neurogranin concentration was significantly lower in
the PD group as compared to the control group (Mann–
Whitney U = 211, P = 0.001). (Not excluding the outlier,
the difference was still significant (Mann–Whitney
U = 150, P = 0.006).) (Fig. 1).
There were no significant correlations between CSF neu-
rogranin concentration and age or sex in either of the diag-
nostic groups (in the PD group, respectively, q = 0.192;
P = 0.319, q = 0.260; P = 0.173, in the control group,
respectively, q = 0.224; P = 0.235, q = 0.283, P = 0.130).
There was a significant correlation between a-synuclein and
age (q = 0.533, P = 0.006) in the PD group.
CSF neurogranin concentrations were significantly cor-
related with the concentrations of CSF Ab38 (q = 0.694;
P < 0.001), Ab40 (q = 0.653; P < .001), Ab42 (q = 0.434;
P = 0.019), and a-synuclein (q = 0.759; P ≤ 0.001). CSF
neurogranin concentrations were significantly inversely
correlated with UPDRS score (q = 0.369; P = 0.039), as
was a-synuclein (q = 0.483, P = 0.020). There were no
significant correlations between UPDRS scores and con-
centrations of CSF Ab38, 40, or 42.
FDG-PET and Ab in patients with PD
There was a significant correlation between CSF Ab42 con-
centrations and FDG-PET uptake in PD; lower CSF Ab42
concentrations were found with more severe reductions on
FDG-PET. The statistical map (Fig. 2) shows decreased cor-
tical metabolism in mainly parietal, frontal, and occipital
areas. For both hemispheres, there was one frontal and one
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posterior (comprising parietal, occipital, and some temporal
vertices) cluster. There were no correlations between CSF
Ab42 concentrations and cortical thickness in PD.
In addition, there was a positive correlation between
CSF Ab38 concentrations and FDG-PET uptake in PD.
The statistical map (Fig. 3) shows the widespread clusters,
most notably posterior lateral areas in which cortical
metabolism correlated with CSF Ab38 concentrations.
There were also slight correlations between CSF Ab40
concentrations and FDG-PET uptake in PD. The
statistical map (Fig. 4) shows small posterior lateral clus-
ters in both hemispheres in which cortical metabolism
correlated with CSF Ab40 concentrations.
FDG-PET and Ab in healthy controls
There were no correlations between CSF Ab42 concentra-
tions and cortical FDG-PET uptake in the control group.
(Not corrected for multiple comparisons, still no voxels
reached the P < 0.01 threshold). Further, there were no
correlations between CSF Ab42 concentrations and corti-
cal thickness in the control group. (Not corrected for
multiple comparisons, with the threshold set at P < 0.01
some small, distributed areas were detected.)
FDG-PET and a-synuclein in patients with PD
There was a significant correlation between CSF total a-
synuclein concentrations and FDG-PET uptake in PD;
Table 1. Overview of demographics and group characteristics.
Parkinson’s disease Healthy controls
N subjects 30 26
Age 65.0 (47–74) years 65.0 (47–81)1
Females/males 11/19 13/132
Education 13.0 (8–19) years 12.6 (8–20)3
MMSE 28.6 (22–30) 28.7 (26–30)4
Geriatric depression
scale score
1.3 (0–6) 1.4 (0–6)5
Duration from motor
symptom onset
2.6 (1–6) years n.a.
UPDRS part III motor
score
15.4 (6–31) n.a.
Hoehn and Yahr stage 1.55 (1–2.5) n.a.
Total daily levodopa
equivalent dose
390.0 (0–924) n.a.
CSF Ab38; ng/L 1877 (819–4551) n.a.
CSF Ab40; ng/L 5125 (2212–10512) n.a.
CSF Ab42; ng/L 943 (707–1280) 987 (634–1290)6
CSF total a-synuclein;
ng/L
278 (160–476)7 n.a.
CSF neurogranin; ng/L 251 (125–556)8 397 (119–988)9,10
Entries are mean (range) unless otherwise stated. Bold entries are sig-
nificantly different from Parkinson’s disease.
Ab, amyloid-b; Ab38, amyloid-b 1-38; Ab40, amyloid-b 1-40; Ab42,
amyloid-b 1-42; MMSE, Mini-Mental State Examination; n.a., not
available; UPDRS, Unified Parkinson’s Disease Rating Scale.
1Age: Parkinson’s disease versus Controls: T-test P = 0.989.
2Gender: Between-group gender composition differences; Pearson
chi-square, P = 0.315.
3Education: Parkinson’s disease versus Controls: Mann–Whitney
U = 349, P = 0.498.
4MMSE: Parkinson’s disease versus. Controls: Mann–Whitney
U = 380, P = 0.864.
5Geriatric depression scale: Parkinson’s disease versus Controls: Mann
–Whitney U = 357.5, P = 0.757.
6Ab42: Parkinson’s disease versus Controls: Mann–Whitney U = 329,
P = 0.312.
7N = 25. Missing for five subjects with Parkinson’s disease.
8Neurogranin: One outlier in the Parkinson’s disease group excluded,
see methods section.
9N = 30 for Controls, see methods section.
10Parkinson’s disease versus Controls: Mann–Whitney U = 211,
P = 0.001.
Table 2. Neuropsychological characteristics of the groups.
Neuropsychological
test battery
Parkinson’s disease
Healthy
controlsBaseline Follow-up
N subjects (missing
neuropsychological
data)
28 (2) 29 (1) 26 (0)
RAVLT delayed verbal
recall of 15 words
after 30 min, T-score
50.4 (31–75) 53.0 (25–71) 47.3 (32–67)1
RCFT delayed visual
reproduction after
30 min, T–score
46.5 (20–75) 60.1 (22–80) n.a.
TMT–A psychomotor
speed, T-score
41.0 (26–62) 47.5 (32–62) n.a.
TMT-B divided
attention, T-score
39.9 (10–59) 47.0 (27–66) 50.2 (28–65)2
SCW response
inhibition, T–score
50.7 (27–67) 50.7 (20–70) 49.0 (20–63)3
COWAT verbal
fluency, T–score
48.1 (33–69) 52.0 (32–73) 48.7 (25–69)4
Entries are mean (range) unless otherwise stated. Bold entries are sig-
nificantly different from Parkinson’s disease at baseline.
Ab, amyloid-b; COWAT, Controlled Oral Word Association Test;
RAVLT, Rey Auditory Verbal Learning Test; RCFT, Rey Complex Fig-
ure Test; SCW, Stroop Color-Word; TMT-A, Trail Making Test-A; TMT-
B, Trail Making Test-B.
1RAVLT delayed verbal recall: Parkinson’s disease versus Controls:
Mann–Whitney U = 297, P = 0.24.
2TMT-B divided attention (available for 25 controls): Parkinson’s dis-
ease versus. Controls: Mann–Whitney U = 207.5, P = 0.011.
3SCW response inhibition: Parkinson’s disease versus Controls: Mann–
Whitney U = 345.5, P = 0.936.
4COWAT verbal fluency (available for 25 controls): Parkinson’s disease
versus Controls: Mann–Whitney U = 331.5, P = 0.728.
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lower CSF total a-synuclein concentrations were found
with more severe reductions on FDG-PET. The statistical
map (Fig. 5) shows decreased cortical metabolism in sev-
eral cortical clusters. Cluster-wise P = 0.0002 for the more
frontal left clusters and the lateral right clusters, and
P = 0.021 for the remaining left, and P = 0.028 for the
remaining right cluster.
There were no correlations between CSF total a-synu-
clein concentrations and cortical thickness in PD.
FDG-PET and neurogranin in patients with
PD
There was a significant correlation between CSF neuro-
granin concentrations and FDG-PET uptake in PD; lower
CSF neurogranin concentrations were found with more
severe reductions on FDG-PET. The statistical map
(Fig. 6) shows decreased cortical metabolism in several
cortical clusters. Cluster-wise P = 0.008 for the lateral left
and P = 0.002 for the medial left cluster, whereas
P = 0.0002 for the single, larger right cluster.
There was a significant correlation between CSF neuro-
granin concentrations and cortical thickness in PD. (Not
shown). There were five small clusters, cluster-wise
P = 0.001 for a frontal left and P = 0.002 for a parietal
left cluster, whereas P = 0.042 for a parietal right, and
P = 0.021 for a frontal, medial right cluster. Also, there
was a right inferior temporal cluster, P = 0.002. The clus-
ters comprised 3% of the left and 3% of the right hemi-
sphere. R2 was 0.655 in the left and 0.630 in the right
combined hemisphere clusters.
Relationship between FDG-PET clusters and
cognition in patients with Parkinson’s
disease
For the cortical areas in which glucose metabolism was
correlated with either CSF Ab38, Ab40, Ab42, total a-
synuclein, or neurogranin, there were strong correlations
between mean FDG uptake and most tests in the neu-
ropsychological test battery, including measures of execu-
tive function (word fluency, response inhibition) and
verbal and visual recall (Table 3). P-values for COWAT
verbal fluency, SCW response inhibition, RAVLT delayed
verbal recall, and RCFT delayed visual reproduction cor-
relations with FDG-PET CSF-based clusters were all
<0.01. Correlations to TMT-B divided attention were not
significant.
Relationship between FDG-PET clusters,
cognition, and cognitive decline in patients
with Parkinson’s disease
For the cortical areas in which glucose metabolism was
correlated with CSF Ab42, there were strong correlations
(P ≤ 0.002) between mean FDG uptake and all tests in
the neuropsychological test battery at baseline (as assessed
by the mixed model approach described above). Only
TMT-A (F = 5.684, P = 0.27) and COWAT verbal fluency
(F = 4.431, P = 0.48) were significantly changed from
baseline to follow-up, and for these tests, FDG-PET clus-
ter uptake was associated with change. (The interaction
between repeated neuropsychological testing and cluster
FDG-PET uptake is a measure of this. F = 5.035,
P = 0.36 for TMT-A and F = 5.041, P = 0.36 for
COWAT verbal fluency). TMT-A performance and verbal
fluency improved, and for both higher FDG-PET uptake
was associated with better performance at follow-up.
Discussion
Combining clinical, imaging, and CSF-proteomic tech-
niques, this study links cortical glucose metabolism to Ab
metabolism, CSF a-synuclein and neurogranin and cogni-
tive impairment in PD. To the best of our knowledge,
this is the first study to explore regional correlations
between FDG-PET, Ab species, and cognition, and also
relate these measures to an independent synaptic marker.
The study results support our initial hypothesis, that is,
that synaptic dysfunction is related to both reduced glu-
cose metabolism and reduced levels of Ab species, puta-
tively related to presynaptic deposition of a-synuclein.
The highly significant associations to a wide range of cog-
nitive functions, including memory and aspects of execu-
tive functions, demonstrate the clinical relevance of our
Figure 1. Median CSF neurogranin concentrations. The median
concentration of CSF neurogranin in patients with mild-to-moderate
Parkinson’s disease and healthy controls, error bars represent 95%
confidence intervals. (Mean CSF neurogranin in the Parkinson’s
disease subjects was 251 (range: 125–556), and in healthy controls,
397 (range: 119–988).)
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findings. Although there was little change in cognitive
performance from baseline to follow-up in the PD on
group level, performance changes were significantly asso-
ciated with FDG-PET.
We describe correlations between CSF Ab38 and Ab42
concentrations and FDG-PET in parietal association,
occipital and lateral frontal areas in PD even though
levels of Ab42 were within normal range for all included
PD subjects. Similar associations were not found in
healthy controls. Furthermore, within these same areas
there were strong FDG-PET correlations to CSF neuro-
granin concentrations. CSF neurogranin was also strongly
correlated with concentrations of the Ab species, and
were significantly reduced compared to healthy controls
at a group level. The broad cortical areas involved are
mirrored by broad and highly significant cognitive associ-
ations.
As described in the introduction, the reduced FDG-
PET signal, the lowered CSF Ab species and the reduced
levels of a-synuclein and neurogranin may all be linked
to reduced synaptic activity. In AD, increased CSF neuro-
granin concentrations probably reflects synaptic degenera-
tion with loss of integrity of postsynaptic spines, that
results in increased CSF levels, and this is hypothesized
specifically for Alzheimer’s disease.37,38 In PD, cortical
presynaptic pathology has been demonstrated in the form
of accumulation of a-synuclein oligomers, accompanied
by loss of dendritic spines but other postsynaptic injury
was not described.5 This is consistent with our present
findings of a reduced CSF neurogranin in the present PD
population as compared to healthy controls. Thus, though
synapses are a focus of both the Alzheimer and PD pro-
cesses, the different mechanisms of attack may explain the
marked differences in neurogranin levels observed in these
diseases.38 The strong association observed here between
CSF a-synuclein and neurogranin is in line with such a
mechanism, but other factors such as altered degradation
or transport mechanisms may also be implicated. Late in
Figure 2. Correlations between FDG-PET and CSF Ab42 in Parkinson’s disease. The statistical map shows two clusters in each hemisphere, one
frontal (yellow) and one posterior (turquoise) cluster, in which cortical metabolism in mild-to-moderate Parkinson’s disease is correlated with CSF
Ab42 concentrations. Mean CSF Ab42 was 943 ng/L (range 707–1280). Cluster-wise P = 0.0001 for all clusters. The clusters comprised 36% of
the total surface area (27% of the left and 45% of the right hemisphere surface area). R2 was 0.389 in the left and 0.433 in the right combined
hemisphere clusters (excluding the effects of age and gender).
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the disease-course PD cases suffer from more extensive
multifactorial neurodegeneration, including amyloid
pathology. The present cohort consisted of early cases
(Table 1, mean disease duration 2.6 years), whereas mean
disease duration in the PD cohort described in ref. 38
was 8 years. If active amyloid-associated neurodegenera-
tion causes the rise of CSF neurogranin in Alzheimer’s
disease, this may possibly explain why the latter cohort
also had higher values than the present cohort. Thus, the
present findings suggest that several disease markers and
clinical parameters like UPDRS and cognitive function
are linked to synaptic dysfunction in PD, and putatively
demonstrate a clinical relevance of CSF neurogranin in
PD via its correlation with the UPDRS motor scale.
Though reduced FDG-PET uptake points to cortical
involvement and the described cortical presynaptic accu-
mulation of a-synuclein points to a cortical focus, we
cannot exclude subcortical pathology as contributing fac-
tors. The nucleus basalis of Meynert (in the basal fore-
brain) has widespread projecting cholinergic neurons to
the entire neocortex, and is known to degenerate in PD
(as well as Alzheimer’s disease), leading to cortical dys-
function and predicting cognitive decline.39–41 Corti-
copetal dopaminergic pathways mainly project to the
frontal cortex. In PD, reduced dopaminergic and cholin-
ergic transmission has been demonstrated in a pattern
coinciding well with the frontal and posterior clusters
demonstrated in the present work.42 As such, the present
findings in the PD group could, hypothetically, be con-
strued as an effect of reduced dopaminergic (the frontal
cluster) and reduced cholinergic transmission (the poste-
rior cluster) in accordance with the dual syndrome
hypothesis. However, here we describe very strong links
between cognition, cortical glucose metabolism, and CSF
Figure 3. Correlations between FDG-PET and CSF Ab38 in Parkinson’s disease. The statistical map shows the three clusters in the left hemisphere
and the two clusters in the right hemisphere in which cortical metabolism in mild-to-moderate Parkinson’s disease is positively correlated with CSF
Ab38 concentrations. For the left hemisphere, cluster-wise P = 0.0001 for the two mainly lateral clusters, whereas for the mainly medial
(precuneal; green) cluster, cluster-wise P = 0.0074. For the right hemisphere, cluster-wise P = 0.0001 for the larger, posterior cluster, whereas
cluster-wise P = 0.00170 for the frontal. The clusters comprised 36% of the total surface area (38% of the left hemisphere surface area, and
33% of the right). R2 was 0.319 in the left and 0.304 in the right combined hemisphere clusters (excluding the effects of age and gender). Mean
CSF Ab38 was 1877 ng/L (range: 819–4551).
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Ab species, both potentially linked to a cortical etiology.
Also, neurobiological underpinnings linking Ab and a-
synuclein physiology in the presynaptic terminal, evidence
for cortical presynaptic buildup of a-synuclein aggregates
and postsynaptic spine retraction is in line with our
demonstration of links to CSF neurogranin and a-synu-
clein, and primary cortical etiology. Although the present
findings do not primarily address mechanistic links, dec-
ades of preplaque Ab pathology including oligomerization
may well influence presynaptic a-synuclein metabolism,
and there is experimental evidence that Ab42 may escalate
production of toxic a-synuclein oligomers – directly dis-
rupting SNARE-dependent vesicle function.43,44
Although we find strong links to Ab, a reverse causality
cannot be excluded, in that synaptic dysfunction could be
due to presynaptic a-synuclein aggregates slightly reduc-
ing Ab in proportion to the degree of a-synuclein-depen-
dent neurodegeneration.5,45 Alternatively, defective
presynaptic proteolysis and lysosomal degradation could
affect both Ab and a-synuclein metabolism.7,8,46 In either
case, postsynaptic spines would be affected secondarily,
likely leading to the observed reduced levels of neuro-
granin. Combined, pre- and postsynaptic dysfunction
would result in loss of clinical and cognitive function as
measured by the UPDRS and the cognitive measures.
Putatively, these hypotheses could be tested or differenti-
ated by also measuring presynaptic markers, like CSF
synaptosomal-associated protein 25 (SNAP25, a compo-
nent of the trans-SNARE complex)47 or synaptotagmin,
expected to be changed if vesicle fusion is truly
hampered.
There are limitations to the current work that needs to
be addressed. The PET scans of the PD and control
groups were acquired on two similar, but not identical
scanners. However, the scan and image reconstruction
parameters, and also the postprocessing procedure were
Figure 4. Correlations between FDG-PET and CSF Ab40 in Parkinson’s disease. The statistical map shows one cluster in the left hemisphere and
two clusters in the right hemisphere in which cortical metabolism in mild-to-moderate Parkinson’s disease is positively correlated with CSF Ab40
concentrations. For the left hemisphere cluster and the right hemisphere occipital cluster, cluster-wise P = 0.0001. For the right hemisphere
parietal cluster (shown in blue), cluster-wise P = 0.0061. The clusters comprised 6% of the total surface area (8% of the left hemisphere surface
area, and 5% of the right). R2 was 0.277 in the left and 0.250 in the right combined hemisphere clusters (excluding the effects of age and
gender). Mean CSF Ab40 was 5125 ng/L (range: 2212–10512).
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identical between the scanners and all analyses were con-
ducted within, and not between, groups. Care should nev-
ertheless be taken when comparing the results between
groups. Also, the sample size in the present work is lim-
ited, and our findings need to be reproduced in other
populations (including drug naive), and although fluctua-
tions are relatively uncommon at the present disease stage
(Hoehn and Yahr stage <3, disease duration <6 years) the
subjects should preferably have been tested at a standard-
ized time in relation to medication. The sample size for
the FDG-PET analyzes with a-synuclein and neurogranin
where even smaller than for Ab, and one might expect
more widespread, significant clusters with a larger sample.
Further, although FDG uptake reflects synaptic function,
there exists no direct or absolute measure of synaptic
function, and this should be taken into account when
interpreting the present results.
All PD subjects had normal levels of CSF Ab42, and
were thus unlikely to harbor amyloid plaques. However, a
presence of soluble, synaptotoxic Ab oligomers cannot be
excluded and could be an alternative explanation for the
present findings related to Ab. Measuring Ab oligomers
in the CSF of patients with PD may be a way to test this
alternative explanation.
We were able to investigate the correlations between
cortical metabolism and the alternative amyloid species
Ab38 and Ab40 (considered less prone to aggregate) in
the PD group, and interestingly the correlations between
FDG-PET and Ab38 were comparable to those with Ab42
(whereas the correlations with Ab40 were more sparse).
As described earlier,18 CSF Ab species and a-synuclein
concentrations correlate strongly, strengthening the sup-
position that presynaptic a-synuclein and Ab metabolism
may interact to produce the current findings.
On group level, the PD patients performed as well as
presumptively healthy controls on neuropsychological
tests except on a measure of divided attention (functions
that may be affected both by impaired dopaminergic and
Figure 5. Correlations between FDG-PET and CSF total a-synuclein in Parkinson’s disease. The statistical map shows the clusters in each
hemisphere in which cortical metabolism in mild-to-moderate Parkinson’s disease is correlated with CSF t-a-syn concentrations. Mean CSF t-a-syn
was 278 (range: 160–476). Cluster-wise P = 0.0002 for the more frontal left clusters and the lateral right clusters, and P = 0.021 for the
remaining left, and P = 0.028 for the remaining right cluster. The clusters comprised 13% of the total surface area (8% of the left and 19% of
the right surface area). R2 was 0.337 in the left and 0.339 in the right combined hemisphere clusters (excluding the effects of age and gender).
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Figure 6. Correlations between FDG-PET and CSF neurogranin in Parkinson’s disease. The statistical map shows the clusters in each hemisphere
in which cortical metabolism in mild-to-moderate Parkinson’s disease is correlated with CSF neurogranin concentrations. Mean CSF neurogranin
was 251 (range: 125–556). Cluster-wise P = 0.008 for the lateral left and P = 0.002 for medial left cluster, whereas P = 0.0002 for the single,
large right cluster. The clusters comprised 10.5% of the total surface area (4% of the left and 16% of the right surface area). R2 was 0.330 in
the left and 0.346 in the right combined hemisphere clusters (excluding the effects of age and gender).
Table 3. Correlations between cognition and mean FDG-PET in cortical clusters related to CSF biomarkers in Parkinson’s disease.
Neuropsychological test battery
FDG-PET CSF biomarker-based cortical clusters
Ab421 Ab381 Ab401 a-synuclein2 Neurogranin3
RAVLT delayed verbal recall of 15 words
after 30 min, T-score
0.566 (0.001) 0.615 (<0.001) 0.651 (<0.001) 0.561 (0.004) 0.616 (<0.001)
RCFT delayed visual reproduction after
30 min, T-score
0.608 (<0.001) 0.655 (<0.001) 0.667 (<0.001) 0.551 (0.005) 0.605 (0.001)
TMT-A divided attention, T-score 0.650 (<0.001) 0.602 (<0.001) 0.607 (<0.001) 0.727 (<0.001) 0.504 (0.005)
TMT-B divided attention, T-score 0.277 (0.145) 0.248 (0.195) 0.283 (0.136) 0.249 (0.252) 0.184 (0.350)
SCW response inhibition, T-score 0.617 (<0.001) 0.613 (<0.001) 0.621 (<0.001) 0.549 (0.005) 0.585 (0.001)
COWAT verbal fluency, T-score 0.499 (0.006) 0.499 (0.006) 0.539 (0.003) 0.653 (0.001) 0.488 (0.008)
Entries are Spearman’s rho Correlation Coefficient (P-value). Bold entries are significant.
Ab, amyloid-b; COWAT, Controlled Oral Word Association Test; RAVLT, Rey Auditory Verbal Learning Test; RCFT, Rey Complex Figure Test; SCW,
Stroop Color-Word; TMT-B, Trail Making Test-B. 1-3Names refer to the clusters significantly correlated with that CSF biomarker.
1N = 30 for RAVLT, RCFT, and SCW. N = 29 for TMT-B, COWAT, WAIS-III.
2N = 24 for RAVLT, RCFT, SCW, and COWAT. N = 23 for TMT-B and WAIS-III.
3N = 29 for RAVLT, RCFT, and SCW. N = 28 for TMT-B, COWAT, and WAIS-III.
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cholinergic networks and frontoparietal hypometabo-
lism48). The present results may have been more informa-
tive were the included PD subjects more cognitively
impaired, or if the time from baseline to follow-up was
longer. However, there were strong correlations between
cortical glucose metabolism and cognitive function in the
PD group. Although there was sparse change in cognition
at 2-year follow-up, cortical metabolism was significantly
associated with this change. We hypothesize that baseline
cortical glucose metabolism will predict further cognitive
change and predict time from disease onset to dementia.
Herein, we describe a correlation between cortical glu-
cose metabolism, cognitive functions, cognitive change,
CSF Ab species, neurogranin, and a-synuclein in PD. The
findings were robust even though CSF Ab42 was within
normal levels for all included subjects with PD, suggesting
that cortical synaptic function is related to cognitive func-
tioning, and is affected in PD. If confirmed, the present
results will have important implications for understanding
the role of synaptic dysfunction, Ab and a-synuclein in
the evolution of PD. We further find lower CSF concen-
trations of neurogranin in these patients with mild-to-
moderate PD, but further studies are needed to assess
whether this may be of clinical relevance. Additionally,
the findings question the previously postulated association
of reduced CSF a-synuclein concentration in PD with
Lewy body pathology, in that reduced CSF a-synuclein
concentration may reflect synaptic degeneration and
reduced release.
Acknowledgments
The authors thank South-Eastern Norway Regional
Health Authority, the Research Council of Norway, Aker-
shus University Hospital, and the University of Oslo for
financial support and all study participants and personnel
for their contributions. KB holds the Torsten S€oderberg
professorship of medicine. HZ is a Wallenberg Academy
Fellow.
Author Contributions
PS drafted the manuscript, contributed to the conception
and design of the study, acquisition and analysis of data.
ALS contributed in revising a substantial portion of the
manuscript and acquisition of data. KKJ contributed in
revising a substantial portion of the manuscript and
acquisition of data. AB contributed to the conception and
design of the study, and acquisition of data. CC con-
tributed to the acquisition and analysis of data. EA, LK,
and ISA revised the manuscript and contributed to the
acquisition of data. EH contributed to the conception
and design of the study, and acquisition of data. HZ, KB,
DA, and TF contributed in the conception and design of
the study as well as acquisition of data and revision of
the manuscript. All authors approved the final draft.
Conflicts of Interest
Dr. Selnes, Dr. Stav, Dr. Johansen, Dr. Bjørnerud, Dr.
Kalheim, Dr. Almdahl, Dr. Hessen, and Dr. Auning have
nothing to disclose. Dr. Coello reports personal fees from
Imanova Ltd, outside the submitted work. Dr. Zetterberg
reports personal fees from Roche Diagnostics, non-finan-
cial support from Eli Lilly, personal fees from Pharmasum
Therapeutics, outside the submitted work; and HZ is co-
founder of Brain Biomarker Solutions in Gothenburg AB,
a GU Venture-based platform company at the University
of Gothenburg. Dr. Blennow reports personal fees from
Fujirebio Europe, personal fees from Roche Diagnostics,
personal fees from IBL International, outside the submit-
ted work; and Co-founder of Brain Biomarker Solutions
in Gothenburg AB, a GU Venture-based platform com-
pany at the University of Gothenburg. Dr. Aarsland
reports personal fees from Novartis, personal fees from H
Lundbeck, grants from Astra-Zeneca, outside the submit-
ted work. Dr. Fladby reports grants from Norwegian
Research Council, grants from EU-JPND, during the con-
duct of the study; in addition, Dr. Fladby has a patent
PCT/EP2009/001210 issued, and a patent PCT/US2011/
062233 pending.
References
1. Aarsland D, Bronnick K, Fladby T. Mild cognitive
impairment in Parkinson’s disease. Curr Neurol Neurosci
Rep 2011;11:371–378.
2. Aarsland D, Brønnick K, Larsen JP, et al. Cognitive
impairment in incident, untreated Parkinson disease: the
Norwegian ParkWest study. Neurology 2009;72:1121–1126.
3. Pienaar IS, Burn D, Morris C, Dexter D. Synaptic protein
alterations in Parkinson’s disease. Mol Neurobiol
2012;45:126–143.
4. Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-
synuclein aggregates, not Lewy bodies, cause
neurodegeneration in dementia with Lewy bodies. J
Neurosci 2007;27:1405–1410.
5. Schulz-Schaeffer WJ. The synaptic pathology of a-
synuclein aggregation in dementia with Lewy bodies,
Parkinson’s disease and Parkinson’s disease dementia. Acta
Neuropathol 2010;120:131–143.
6. Kvartsberg H, Duits FH, Ingelsson M, et al. Cerebrospinal
fluid levels of the synaptic protein neurogranin correlates
with cognitive decline in prodromal Alzheimer’s disease.
Alzheimers Dement 2015;11:1180–1190.
7. Sevlever D, Jiang P, Yen S-HC Cathepsin d is the main
lysosomal enzyme involved in the degradation of a-
ª 2017 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 711
P. Selnes et al. Synaptic Function in Parkinson’s Disease
synuclein and generation of its carboxy-terminally
truncated species†. Biochemistry 2008;47:9678–9687.
8. Saido T, Leissring MA. Proteolytic degradation of amyloid
b-protein. Cold Spring Harb Perspect Med 2012;2:
a006379–a006379.
9. Hetz C, Mollereau B. Disturbance of endoplasmic
reticulum proteostasis in neurodegenerative diseases. Nat
Rev Neurosci 2014;15:233–249.
10. Laßek M, Weingarten J, Wegner M, Volknandt W. The
amyloid precursor protein-a novel player within the
molecular array of presynaptic nanomachines. Front
Synaptic Neurosci 2015;7:21.
11. Cirrito JR, Kang J-E, Lee J, et al. Endocytosis is required
for synaptic activity-dependent release of amyloid-beta
in vivo. Neuron 2008;58:42–51.
12. Checler F. Processing of the beta-amyloid precursor
protein and its regulation in Alzheimer’s disease. J
Neurochem 1995;65:1431–1444.
13. Blennow K, Dubois B, Fagan AM, et al. Clinical utility of
cerebrospinal fluid biomarkers in the diagnosis of early
Alzheimer’s disease. Alzheimers Dement 2015;11:58–69.
14. Parnetti L, Castrioto A, Chiasserini D, et al. Cerebrospinal
fluid biomarkers in Parkinson disease. Nat Rev Neurol
2013;9:131–140.
15. Stav AL, Aarsland D, Johansen KK, et al. Amyloid-b and
a-synuclein cerebrospinal fluid biomarkers and cognition
in early Parkinson’s disease. Parkinsonism Relat Disord
2015;21:758–764.
16. Alves G, Bronnick K, Aarsland D, et al. CSF amyloid-b
and tau proteins, and cognitive performance, in early and
untreated Parkinson’s Disease: the Norwegian ParkWest
study. J Neurol Neurosurg Psychiatry 2010;81:1080–1086.
17. Leverenz JB, Watson GS, Shofer J, Zabetian CP.
Cerebrospinal fluid biomarkers and cognitive performance
in non-demented patients with Parkinson’s disease.
Parkinsonism Relat Discord 2011;17:61–64.
18. Stav AL, Johansen KK, Auning E, et al. Hippocampal
subfield atrophy in relation to cerebrospinal fluid
biomarkers and cognition in early Parkinson’s disease: a
cross-sectional study. NPJ Parkinson’s Dis 2016;2:15030.
19. Cummings DM, Liu W, Portelius E, et al. First effects of
rising amyloid-b in transgenic mouse brain: synaptic
transmission and gene expression. Brain 2015;138:awv127–
awv2004.
20. Patterson BW, Elbert DL, Mawuenyega KG, et al. Age and
amyloid effects on human central nervous system amyloid-
beta kinetics. Ann Neurol 2015;78:439–453.
21. Burton EJ, McKeith IG, Burn DJ, et al. Cerebral atrophy
in Parkinson’s disease with and without dementia: a
comparison with Alzheimer’s disease, dementia with Lewy
bodies and controls. Brain 2004;127:791–800.
22. Compta Y, Ibarretxe-Bilbao N, Pereira JB, et al. Grey
matter volume correlates of cerebrospinal markers of
Alzheimer-pathology in Parkinson’s disease and related
dementia. Parkinsonism Relat Disord 2012;18:941–947.
23. Beyer MK, Alves G, Hwang KS, et al. Cerebrospinal fluid
Ab levels correlate with structural brain changes in
Parkinson’s disease. Mov Disord 2013;28:302–310.
24. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic
topography of Parkinsonism. J Cereb Blood Flow Metab
1994;14:783–801.
25. Borghammer P. Perfusion and metabolism imaging studies
in Parkinson’s disease. Dan Med J 2012;59:B4466.
26. Rocher AB, Chapon F, Blaizot X, et al. Resting-state brain
glucose utilization as measured by PET is directly related
to regional synaptophysin levels: a study in baboons.
NeuroImage 2003;20:1894–1898.
27. Jokinen P, Scheinin N, Aalto S, et al. [(11)C]PIB-, [(18)F]
FDG-PET and MRI imaging in patients with Parkinson’s
disease with and without dementia. Parkinsonism Relat
Disord 2010;16:666–670.
28. Liepelt I, Reimold M, Maetzler W, et al. Cortical
hypometabolism assessed by a metabolic ratio in
Parkinson’s disease primarily reflects cognitive
deterioration—[18F]FDG-PET. Mov Disord 2009;24:1504–
1511.
29. Bereczki E, Francis PT, Howlett D, et al. Synaptic proteins
predict cognitive decline in Alzheimer’s disease and Lewy
body dementia. Alzheimer’s Dement 2016;12:1149–1158.
30. Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-
ES/ENS [corrected] recommendations for the diagnosis of
Parkinson’s disease. Eur J Neurol 2013;20:16–34.
31. Hessen E, Stav AL, Auning E, et al. Neuropsychological
profiles in mild cognitive impairment due to Alzheimer”s
and Parkinson”s Diseases. J Parkinsons Dis 2016;6:413–
421.
32. Rey Auditory Verbal Learning Test[Internet]. Los Angeles:
Western Psychological Services; 1996. Available from:
http://books.google.no/books?id=UOcPRAAACAAJ&dq=
intitle:Rey+Auditory+and+Verbal+Learning+Test+A+ha
ndbook+inauthor:schmidt&hl=&cd=1&source=gbs_api
(Accessed March 2, 2017)
33. Fischl B, Salat DH, Busa E, et al. Whole brain
segmentation: automated labeling of neuroanatomical
structures in the human brain. Neuron 2002;33:341–355.
34. Desikan RS, Segonne F, Fischl B, et al. An automated
labeling system for subdividing the human cerebral cortex
on MRI scans into gyral based regions of interest.
NeuroImage 2006;31:968–980.
35. Selnes P, Grambaite R, Rincon M, et al. Hippocampal
complex atrophy in poststroke and mild cognitive
impairment. J Cereb Blood Flow Metab 2015;35:1729–
1737.
36. Hagler DJ, Saygin AP, Sereno MI. Smoothing and cluster
thresholding for cortical surface-based group analysis of
fMRI data. NeuroImage 2006;33:1093–1103.
712 ª 2017 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Synaptic Function in Parkinson’s Disease P. Selnes et al.
37. Thorsell A, Bjerke M, Gobom J, et al. Neurogranin in
cerebrospinal fluid as a marker of synaptic
degeneration in Alzheimer’s disease. Brain Res
2010;1362:13–22.
38. Wellington H, Paterson RW, Portelius E, et al. Increased
CSF neurogranin concentration is specific to Alzheimer
disease. Neurology 2016;86:829–835.
39. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical
cholinergic function is more severely affected in
parkinsonian dementia than in Alzheimer disease: an
in vivo positron emission tomographic study. Arch Neurol
2003;60:1745–1748.
40. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive
correlates of cortical cholinergic denervation in
Parkinson’s disease and parkinsonian dementia. J Neurol
2006;253:242–247.
41. Gratwicke J, Kahan J, Zrinzo L, et al. The nucleus basalis
of Meynert: a new target for deep brain stimulation in
dementia? Neurosci Biobehav Rev 2013;37(10 Pt 2):2676–
2688.
42. Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter
changes in dementia with Lewy bodies and Parkinson
disease dementia in vivo. Neurology 2010;74:885–892.
43. Lesne SE, Sherman MA, Grant M, et al. Brain amyloid-b
oligomers in ageing and Alzheimer’s disease. Brain
2013;136:awt062–awt1398.
44. Choi B-K, Kim J-Y, Cha M-Y, et al. b-Amyloid and a-
synuclein cooperate to block SNARE-dependent vesicle
fusion. Biochemistry 2015;54:1831–1840.
45. Rockenstein E, Nuber S, Overk CR, et al. Accumulation of
oligomer-prone -synuclein exacerbates synaptic and
neuronal degeneration in vivo. Brain 2014;137:1496–1513.
46. Bingol B, Sheng M. Deconstruction for reconstruction: the
role of proteolysis in neural plasticity and disease. Neuron
2011;69:22–32.
47. Rizo J, S€udhof TC. Snares and munc18 in synaptic vesicle
fusion. Nat Rev Neurosci 2002;3:641–653.
48. Gratwicke J, Jahanshahi M, Foltynie T. Parkinson’s disease
dementia: a neural networks perspective. Brain 2015;1454–
1476.
ª 2017 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 713
P. Selnes et al. Synaptic Function in Parkinson’s Disease
